253 related articles for article (PubMed ID: 15660621)
1. Role of the standard deviation in the estimation of benchmark doses with continuous data.
Gaylor DW; Slikker W
Risk Anal; 2004 Dec; 24(6):1683-7. PubMed ID: 15660621
[TBL] [Abstract][Full Text] [Related]
2. Effects of exposure imprecision on estimation of the benchmark dose.
Budtz-Jørgensen E; Keiding N; Grandjean P
Risk Anal; 2004 Dec; 24(6):1689-96. PubMed ID: 15660622
[TBL] [Abstract][Full Text] [Related]
3. Precision of benchmark dose estimates for continuous (nonquantal) measurements of toxic effects.
Gaylor DW; Chen JJ
Regul Toxicol Pharmacol; 1996 Aug; 24(1 Pt 1):19-23. PubMed ID: 8921542
[TBL] [Abstract][Full Text] [Related]
4. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
Zhu Y; Wang T; Jelsovsky JZ
Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
[TBL] [Abstract][Full Text] [Related]
5. A procedure for developing risk-based reference doses.
Gaylor DW; Kodell RL
Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
[TBL] [Abstract][Full Text] [Related]
6. Quantalization of continuous data for benchmark dose estimation.
Gaylor DW
Regul Toxicol Pharmacol; 1996 Dec; 24(3):246-50. PubMed ID: 8975754
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD).
Gaylor DW; Aylward LL
Regul Toxicol Pharmacol; 2004 Aug; 40(1):9-17. PubMed ID: 15265602
[TBL] [Abstract][Full Text] [Related]
8. Procedures for calculating benchmark doses for health risk assessment.
Gaylor D; Ryan L; Krewski D; Zhu Y
Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
[TBL] [Abstract][Full Text] [Related]
9. Calculation of benchmark doses from teratology data.
Auton TR
Regul Toxicol Pharmacol; 1994 Apr; 19(2):152-67. PubMed ID: 8041913
[TBL] [Abstract][Full Text] [Related]
10. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
Slob W; Moerbeek M; Rauniomaa E; Piersma AH
Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
[TBL] [Abstract][Full Text] [Related]
11. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
Filipsson AF; Sand S; Nilsson J; Victorin K
Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
[TBL] [Abstract][Full Text] [Related]
12. Statistical analysis of nonmonotonic dose-response relationships: research design and analysis of nasal cell proliferation in rats exposed to formaldehyde.
Gaylor DW; Lutz WK; Conolly RB
Toxicol Sci; 2004 Jan; 77(1):158-64. PubMed ID: 14600280
[TBL] [Abstract][Full Text] [Related]
13. Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.
Gaylor DW; Swirsky Gold L
Regul Toxicol Pharmacol; 1998 Dec; 28(3):222-5. PubMed ID: 10049793
[TBL] [Abstract][Full Text] [Related]
14. Comparing experimental designs for benchmark dose calculations for continuous endpoints.
Kuljus K; von Rosen D; Sand S; Victorin K
Risk Anal; 2006 Aug; 26(4):1031-43. PubMed ID: 16948695
[TBL] [Abstract][Full Text] [Related]
15. A probabilistic framework for non-cancer risk assessment.
Chen JJ; Moon H; Kodell RL
Regul Toxicol Pharmacol; 2007 Jun; 48(1):45-50. PubMed ID: 17166641
[TBL] [Abstract][Full Text] [Related]
16. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
Bokkers BG; Slob W
Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
[TBL] [Abstract][Full Text] [Related]
17. The current state of knowledge on the use of the benchmark dose concept in risk assessment.
Sand S; Victorin K; Filipsson AF
J Appl Toxicol; 2008 May; 28(4):405-21. PubMed ID: 17879232
[TBL] [Abstract][Full Text] [Related]
18. Benchmark dose approaches in chemical health risk assessment in relation to number and distress of laboratory animals.
Oberg M
Regul Toxicol Pharmacol; 2010 Dec; 58(3):451-4. PubMed ID: 20800084
[TBL] [Abstract][Full Text] [Related]
19. Identification of a critical dose level for risk assessment: developments in benchmark dose analysis of continuous endpoints.
Sand S; von Rosen D; Victorin K; Filipsson AF
Toxicol Sci; 2006 Mar; 90(1):241-51. PubMed ID: 16322076
[TBL] [Abstract][Full Text] [Related]
20. Multiplicity-adjusted inferences in risk assessment: benchmark analysis with quantal response data.
Nitcheva DK; Piegorsch WW; West RW; Kodell RL
Biometrics; 2005 Mar; 61(1):277-86. PubMed ID: 15737104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
